Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lukas John
Observed names:
John L,
John, Lukas,
L John,
L. John
Institutions:
University of Hohenheim,
German Cancer Research Center,
Heidelberg University,
University Hospital Heidelberg
Observed institutions:
University of Hohenheim,
University of Helsinki,
University of Calgary,
German Cancer Research Center,
Heidelberg University,
Helsinki University Hospital,
University Hospital Heidelberg,
National Center for Tumor Diseases,
Dana-Farber Cancer Institute,
University of Bologna
show all 10
ORCID:
0000-0001-8178-6890
Observed ORCIDs:
0000-0001-8178-6890,
0009-0002-8052-3946
OpenAlex ID:
A5001651530
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomics
2021
·
Stephan M. Tirier
, Jan-Philipp Mallm
, et al.
·
Nature Communications
·
156
PDF
Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis
2023
·
Alexandra M. Poos
, Nina Prokoph
, et al.
·
Blood
·
69
PDF
Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
2022
·
Carolina Schinke
, Alexandra M. Poos
, et al.
·
Blood Advances
·
69
Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level
2023
·
Lukas John
, Alexandra M. Poos
, et al.
·
Nature Communications
·
52
PDF
Application of an artificial intelligence-based tool in [18F]FDG PET/CT for the assessment of bone marrow involvement in multiple myeloma
2023
·
Christos Sachpekidis
, Olof Enqvist
, et al.
·
European Journal of Nuclear Medicine and Molecular Imaging
·
35
PDF
Pathway-Directed Therapy in Multiple Myeloma
2021
·
Lukas John
, Maria Theresa Krauth
, et al.
·
Cancers
·
34
PDF
Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma
2025
·
Raphael Lutz
, Alexandra M. Poos
, et al.
·
Science Immunology
·
27
Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma
2024
·
Anna Luise Grab
, Peter S. Kim
, et al.
·
Cells
·
25
Temporal genomic dynamics shape clinical trajectory in multiple myeloma
2025
·
Francesco Maura
, Marcella Kaddoura
, et al.
·
Nature Genetics
·
18
PDF
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma
2024
·
Anthony M. Cirrincione
, Alexandra M. Poos
, et al.
·
Blood
·
15
PDF
Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant
2024
·
Peter Langer
, Lukas John
, et al.
·
Cochrane Database of Systematic Reviews
·
12
PDF
High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders
2023
·
Sebastian Köhrer
, Tobias Dittrich
, et al.
·
Leukemia
·
11
PDF
Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation
2023
·
Lukas John
, Sandra Sauer
, et al.
·
Transplantation and Cellular Therapy
·
11
Comprehensive Comparison of Early Relapse and End-Stage Relapsed Refractory Multiple Myeloma
2020
·
Alexandra M Poos
, Nicola Giesen
, et al.
·
Blood
·
9
Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma
2023
·
Lukas John
, Kaya Miah
, et al.
·
Frontiers in Oncology
·
8
Investigating the bHLH transcription factor TSARL1 as marker and regulator of saponin biosynthesis in Chenopodium quinoa
2025
·
Marius Kollmar
, Katharina B. Böndel
, et al.
·
Journal of the Science of Food and Agriculture
·
7
PDF
The Spatial Heterogeneity in Newly Diagnosed Multiple Myeloma Patients - from Sub-Clonal Architecture to the Immune Microenvironment
2021
·
Lukas John
, Alexandra Poos
, et al.
·
Blood
·
6
Bone Marrow Immune Signatures in Multiple Myeloma Are Linked to Tumor Heterogeneity and Treatment Outcome
2022
·
Simon Steiger
, Raphael Lutz
, et al.
·
Blood
·
5
Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [18F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 Trial
2025
·
Christos Sachpekidis
, Marina Hajiyianni
, et al.
·
European Journal of Nuclear Medicine and Molecular Imaging
·
4
PDF
Clinical and serological characterization of acute pleuropericarditis suggests an autoinflammatory pathogenesis and highlights risk factors for recurrent attacks
2024
·
Dorothee Kaudewitz
, Lukas John
, et al.
·
Clinical Research in Cardiology
·
4
PDF
Is quinoa‐farming sustainable in marginal environments? Social, economical and environmental aspects
2026
·
Anna Tabea Mengen
, Damir Esenaliev
, et al.
·
Journal of the Science of Food and Agriculture
·
3
Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease
2024
·
Kylee H Maclachlan
, Juan-Jose Garces
, et al.
·
Blood
·
3
The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations
2023
·
Duoduo Zhao
, Christian Rohde
, et al.
·
Leukemia
·
3
PDF
OA-23 Resolving therapy resistance mechanisms in multiple myeloma by multi-omics subclone analysis
2023
·
Alexandra Poos
, Nina Prokoph
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
2
Efficacy and Safety of Daratumumab for the Treatment of Multiple Myeloma: a Series of Cochrane Reviews
2021
·
C. Hirsch
, V. Piechotta
, et al.
·
Hematological Oncology
·
2
Show more works
View as search
Works count:
61
Citation count:
597
H-index:
11
I10-index:
13
Year
Topic
Type